Precipio Inc. Common Sto... (PRPO)
NasdaqCM: PRPO
· Real-Time Price · USD
27.85
+3.16 (12.80%)
At close: Aug 19, 2026, 3:59 PM
Precipio Inc. Common Stock (PRPO) Stock Price, Analysis & Data
12.80% (1D)
| Bid | 23.14 |
| Market Cap | 49.86M |
| Revenue (ttm) | 25.83M |
| Net Income (ttm) | -922K |
| Beta | 1.29 |
| EPS (ttm) | -0.62 |
| PE Ratio (ttm) | n/a |
| Forward PE | 71.41 |
| P/B (ttm) | 3.51 |
| P/S (ttm) | 1.93 |
| Earnings Date | n/a |
| Ask | 31.66 |
| Volume | 91,112 |
| Avg. Volume (20D) | 75,854 |
| Open | 25.01 |
| Previous Close | 24.69 |
| Day's Range | 24.86 - 27.85 |
| 52-Week Range | 14.04 - 33.63 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PRPO
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-ph...
Industry Diagnostics & Research
Sector Healthcare
IPO Date Jun 30, 2017
Employees 61
Stock Exchange NasdaqCM
Ticker Symbol PRPO
Website https://www.precipiodx.com
Financial Performance
In 2025, Precipio Common Stock's revenue was 24.05M, an increase of 29.77% compared to the previous year's 18.53M. Earnings were -363K, a decrease of -91.54%.
Financial StatementsEarnings Surprise
Precipio Common Stock has released their quarterly earnings on Nov 13, 2023:
Page 1 of 2